The Active Is Familiar. The Topical Product Can Still Be New.

The active does not define the whole product

Two late-August developments involved familiar topical medicines. China’s drug-approval delivery notice listed a flurbiprofen gel patch from Jiangsu Wango Pharmaceutical. In Canada, WYNZORA, a cream combining calcipotriol and betamethasone dipropionate, entered the market. The first is a generic patch; the second packages an established combination in a different cream system. They are not equivalent kinds of innovation, but both put the finished dosage form in view. ^{[1, 2]}

A registration notice does not reveal how a patch compares with competitors on adhesion, release, residue, skin irritation, or cost. Each is a product question that needs its own evidence. The approval listing establishes the regulatory event, not a performance advantage for this manufacturer. ^[1]

A cream still had to be tested as a cream

Health Canada’s database lists WYNZORA as a marketed prescription cream containing calcipotriol 0.05 mg/g and betamethasone dipropionate 0.5 mg/g. The Canadian product monograph reports two eight-week adult phase III studies that compared the cream with its vehicle and same-active products in other formulations. Those comparisons matter: using known actives did not remove the need to test the actual cream. ^{[2, 3]}

One published study enrolled 490 adults with mild-to-moderate psoriasis. At week eight, the cream produced a greater mean reduction in modified Psoriasis Area and Severity Index than vehicle and met the study’s noninferiority comparison with a same-active gel. Participants also rated treatment convenience more favorably than the gel. These findings belong to WYNZORA under the study conditions; they do not establish the performance of every cream built with its developer’s formulation technology. ^{[3, 4]}

Formulation changes the questions to answer

A patch must stay in contact with moving skin while controlling dose and release. A cream must remain stable, spread acceptably, and deliver an appropriate amount to the intended site. Neither product can borrow those answers from an active ingredient’s history. For development teams, the practical sequence is to define the target tissue and use case, select the dosage form, then measure the finished product against relevant comparators. These two products illustrate that sequence; N1 Life was not involved in either program.

Sources

1. National Medical Products Administration, drug-approval document delivery information, August 27, 2026; Jiangsu Wango Pharmaceutical flurbiprofen gel patch, approval H20265760 (official page screenshot retained in the Marketing source package).
2. Health Canada Drug Product Database. WYNZORA, DIN 02563010.
3. Knight Therapeutics. WYNZORA Canadian Product Monograph.
4. Pinter A, et al. Randomized phase 3 trial of a calcipotriol and betamethasone dipropionate cream. JEADV. 2023;37:2327–2335.